Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 31/07/2019.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques importées :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | DATE courrier |
1 | PRAXBIND | IDARUCIZUMAB | 2,5G/50ML | SOL INJ PERFUSION | B/2FL/50ML | BOEHRINGER INGELHEIM | V | N | 15/03/2019 |
2 | MIRVASO | BRIMONIDINE TARTRATE | 3mg/gr | Gel dermique | T / 30gr | GALDERMA INTERNATIONAL | C | N | 22/05/2019 |
3 | XARELTO | RIVAROXABAN | 15mg | Cp | B42 | BAYER | E | N | 29/05/2019 |
4 | XARELTO | RIVAROXABAN | 15mg | Cp | B28 | BAYER | E | N | 29/05/2019 |
5 | XARELTO | RIVAROXABAN | 20mg | Cp | B28 | BAYER | E | N | 29/05/2019 |
6 | PRADAXA | DABIGATRAN | 150 MG | GELULE | B/60 | BOEHRINGER ING.INT.GmbH | E | N | 14/06/2019 |
7 | PRADAXA | DABIGATRAN | 110 MG | GELLULE | B/60 | BOEHRINGER ING.INT.GmbH | E | V | 14/06/2019 |
8 | PRADAXA | DABIGATRAN | 110 MG | GELLULE | B/30 | BOEHRINGER ING.INT.GmbH | E | V | 14/06/2019 |
9 | LUCENTIS | RANIBIZUMAB | 10MG/ML | SOL INJ | B/1FL | NOVARTIS | E | V | 27/06/2019 |
10 | SANDOSTATINE LAR | OCTREOTIDE | 10MG | PDRE P SUSP INJ | B/1 | NOVARTIS | E | V | 05/07/2019 |
11 | SANDOSTATINE LAR | OCTREOTIDE | 20 MG | PDRE P SUSP INJ | B/1 | NOVARTIS | E | V | 05/07/2019 |
12 | SANDOSTATINE LAR | OCTREOTIDE | 30 MG | PDRE P SUSP INJ | B/1 | NOVARTIS | E | V | 05/07/2019 |
13 | SOMATULINE LP | LANREOTIDE | 60 MG | PDRE P SUSP INJ | B/1 | IPSEN PHARMA | E | V | 05/07/2019 |
14 | SOMATULINE LP | LANREOTIDE | 90 MG | PDRE P SUSP INJ | B/1 | IPSEN PHARMA | E | V | 05/07/2019 |
15 | SOMATULINE LP | LANREOTIDE | 120 MG | PDRE P SUSP INJ | B/1 | IPSEN PHARMA | E | V | 05/07/2019 |
16 | DUOPlAVIN | CLOPIDOGREL+ ACIDE ACETYLSALICYLIQUE | 75mg/100mg | CP PELLICULE | B/28 | SANOFI AVENTIS | E | N | 12/07/2019 |
17 | XTANDI | ENZALUTAMIDE | 40 MG | CAPSULE MOLLE | B/112 | ASTELLAS | E | N | 15/07/2019 |
18 | BETMIGA | MIRABEGRON | 50MG | COMP LIB PRO | B/30 | ASTRELLAS | E | N | 16/07/2019 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE |
1 | FRAXIPARINE | NADROPARINE CALCIUM | 5700 UI AXA/0,6ML | SOL INJ | B/2 | ASPEN PHARMA | E | V | CS 03/05/2019 |
2 | FRAXIPARINE | NADROPARINE CALCIUM | 2850 UI Axa | SOL INJ | B/2 | ASPEN PHARMA | E | V | CS 03/05/2019 |
3 | BECLOSPIN | BECLOMETASONE | 800 MG/2ML | SUSP INH | B/20 | CHIESI SAS | E | V | CS 03/05/2019 |
4 | BECLOSPIN | BECLOMETASONE | 400 MG/ML | SUSP INH | B/20 | CHIESI SAS | E | V | CS 03/05/2019 |
5 | LIDOCAINE ADRENALINE | CHLORHYDRATE DE LIDOCAINE /TARTRATE D'ADRENALINE | 20 MG/ML 0,005MG/ML | SOL INJ | B/10 | AGUETTANT France | E | V | CS 03/05/2019 |
6 | LIDOCAINE ADRENALINE | CHLORHYDRATE DE LIDOCAINE /TARTRATE D'ADRENALINE | 10 MG/ML 0,005MG/ML | SOL INJ | B/10 | AGUETTANT France | E | V | CS 03/05/2019 |
7 | XARELTO | RIVAROXABAN | 10 MG | COMPRIME | B/10 | BAYER Allemagne | T/V | CS 03/05/2019 | |
8 | XARELTO | RIVAROXABAN | 10 MG | COMPRIME | B/30 | BAYER Allemagne | T/V | CS 03/05/2019 | |
9 | EZETROL | EZETIMIBE | 10 MG | COMPRIME | B/28 | MSD-SP Ltd | E | V | CS 03/05/2019 |
10 | TAHOR | ATORVASTATINE | 80 MG | COMPRIME | B/30 | PFIZER France | E | V | CS 03/05/2019 |
11 | MENAVEN | HEPARINE SODIQUE | 1000UI/G | GEL DERMIQUE | T/60 GR | MENARINI | C | V | CS 03/05/2019 |
12 | COOLMETEC | OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE | 40 MG/12,5MG | COMPRIME | B/30 | DAIICHI SANKYO | E | V | CS 03/05/2019 |
13 | COOLMETEC | OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE | 40 MG/25MG | COMPRIME | B/30 | DAIICHI SANKYO | E | V | CS 03/05/2019 |
14 | LOVENOX | ENOXAPARINE | 8000 UI/0,8 ML | SOL INJ | B/2 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
15 | LOVENOX | ENOXAPARINE | 6000 UI/0,6ML | SOL INJ | B/2 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
16 | LOVENOX | ENOXAPARINE | 4000 UI/0,4ML | SOL INJ | B/2 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
17 | LOVENOX | ENOXAPARINE | 2000 UI/0,2ML | SOL INJ | B/2 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
18 | LOVENOX | ENOXAPARINE | 6000 UI/0,6ML | SOL INJ | B/10 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
19 | LOVENOX | ENOXAPARINE | 4000 UI/0,4ML | SOL INJ | B/6 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
20 | LOVENOX | ENOXAPARINE | 8000 UI/0,8ML | SOL INJ | B/10 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
21 | LOVENOX | ENOXAPARINE | 2000 UI/0,2ML | SOL INJ | B/6 | SANOFI AVENTIS | E | V | CS 03/05/2019 |
22 | INNOHEP | TINZAPARINE SODIQUE | 3500 UI/0,35ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
23 | INNOHEP | TINZAPARINE SODIQUE | 14000 UI/0,7ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
24 | INNOHEP | TINZAPARINE SODIQUE | 18000 UI/0,9ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
25 | INNOHEP | TINZAPARINE SODIQUE | 2500 UI/0,25ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
26 | INNOHEP | TINZAPARINE SODIQUE | 10000 UI/0,5ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
27 | INNOHEP | TINZAPARINE SODIQUE | 4500 UI/0,45ML | SOL INJ | B/2 | LEO | E | V | CS 03/05/2019 |
28 | PICOPREP | PICOSULFATE DE SODIUM, OXYDE DE MAGNESIUM LEGER,ACIDE CITRIQUE ANHYDRE | 10,0MG/3,5G/12,0G | PDRE PR SOL BUV | B/02 SACHETS | FERRING ARZNEIMITTEL GmbH | E | T | Transfert 07/05/2019 |
29 | LIBLAB | EXTRAIT DE SEC DE FEUILLES DE LIERRE | 35,7 MG | COMPRIME A SUCER | B/20 | DAR EL DAWA | C | N | 10/05/2019 |
30 | RISDONE | RISPERIDONE | 1MG/ML | SOL BUVABLE | FL/60ML | DAR EL DAWA | E | N | 10/05/2019 |
31 | RISDONE | RISPERIDONE | 1 MG/ML | SOL BUVABLE | FL/30ML | DAR EL DAWA | E | N | 10/05/2019 |
32 | SOLUVIT | MELANGE DES VITAMINES HYDROSOLUBLES | LYOPHILISAT PREP INJ | b/10/10ML | FRESENIUS KABI | C | N | 10/05/2019 | |
33 | CERTICAN | EVEROLIMUS | 0,5 MG | COMPRIME | b/60 | NOVARTIS PHARMA | V | N | 13/05/2019 |
34 | SIMULECT | BASILIXIMAB | 20 MG | PDRE P PREP INJ | B/1F + S /5ML | NOVARTIS PHARMA | V | T | CS 16/05/2019 |
35 | ASPEGIC | ACETYL SALICYLATE DE LYSINE | 500 MG | PDRE PPREP INJ | B/20 FL | SANOFI AVENTIS | E | V | CS 16/05/2019 |
36 | ASPEGIC | ACETYL SALICYLATE DE LYSINE | 500 MG | PDRE PPREP INJ | B/6 FL | SANOFI AVENTIS | E | V | CS 16/05/2019 |
37 | OXYNORM | OXYCODONE (HCL) | 10 MG | SOL INJ | B/5 AMP/1ML | NAPP PHARMACEUTICALS LIMITED | V | N | CS 16/05/2019 |
38 | OXYNORM | OXYCODONE (HCL) | 20 MG | SOL INJ | B/5 AMP/2ML | NAPP PHARMACEUTICALS LIMITED | V | N | CS 16/05/2019 |
39 | OXYCONTIN | OXYCODONE (HCL) | 80 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
40 | OXYCONTIN | OXYCODONE (HCL) | 10 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
41 | OXYCONTIN | OXYCODONE (HCL) | 15 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
42 | OXYCONTIN | OXYCODONE (HCL) | 20 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
43 | OXYCONTIN | OXYCODONE (HCL) | 30 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
44 | OXYCONTIN | OXYCODONE (HCL) | 40 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
45 | OXYCONTIN | OXYCODONE (HCL) | 60 MG | COMPRIME LP | B/20 | PURDUE PHARMA L.P | E | N | CS 16/05/2019 |
46 | BUTRANS | BUPRENORPHINE | 5µG/H | PATCHS TRANSDERMIQUE | B/4 PATCHS | NAPP PHARMACEUTICALS LIMITED | V | N | CS 16/05/2019 |
47 | BUTRANS | BUPRENORPHINE | 10µG/H | PATCHS TRANSDERMIQUE | B/4 PATCHS | NAPP PHARMACEUTICALS LIMITED | V | N | CS 16/05/2019 |
48 | BUTRANS | BUPRENORPHINE | 20µG/H | PATCHS TRANSDERMIQUE | B/4 PATCHS | NAPP PHARMACEUTICALS LIMITED | V | N | CS 16/05/2019 |
49 | LEUPRO SANDOZ | LEUPRORELINE | 3,6MG | SERINGUE PRE REMPL | B/01 | SANDOZ PHARMA | V | N | 09/06/2019 |
50 | LEUPRO SANDOZ | LEUPRORELINE | 5 MG | SERINGUE PRE REMPL | B/01 | SANDOZ PHARMA | V | N | 09/06/2019 |
51 | GRANOCYTE | LENOGRASTIM | 34MUI/ML | POUDRE ET SOLVANT POUR SOLUTION INJECTABLE | B/05 | SANOFI | V | N | 19/06/2019 |
52 | CANCIDAS | CASPOFUNGINE | 50 MG | PDRE P PREP INJ | B/01 | MERCK SHARP &DOHME BV | E | N | 21/06/2019 |
53 | CANCIDAS | CASPOFUNGINE | 70 MG | PDRE P PREP INJ | B/01 | MERCK SHARP &DOHME BV | E | N | 21/06/2019 |
54 | VFEND | VORICONAZOLE | 200MG | PDRE PR SOL PERFUSION | B/1 | PFIZER EUROPE | E | N | TRANSFERT 27/06/2019 |
55 | XALAtAN | LATANOPROST | 50µG/ML | COLLYRE | B/3FL2,5ML | PFIZER HOLDING | E | V | CS 09/07/2019 |
56 | XALAtAN | LATANOPROST | 50µG/MG | COLLYRE | B/1/FL2,5ML | PFIZER HOLDING | E | V | CS 09/07/2019 |
57 | XALAtAN | LATANOPROST+ TIMOLOL | 50µG/5MG | COLLYRE | FL/1FL | PFIZER HOLDING | E | V | CS 09/07/2019 |
58 | XALAtAN | LATANOPROST+ TIMOLOL | 50µG/5ML | COLLYRE | B/3F | PFIZER HOLDING | E | V | CS 09/07/2019 |
59 | DAISYNELLE | DESOGESTREL+ ETHINYLOESTRADIOL | 150/20µG | COMPRIME | B/21 | STRAGEN | E | N | 18/07/2019 |
60 | ARNICA COMPLEXE N01 | ARNICA | SOL BUVABLE EN GOUTTES | FL/30ML | LEHNING | C | N | 18/07/2019 | |
61 | ADOL | JULPHAR UAE | 100MG/ML | GOUTTES BUVABLES | FL/15ML | JULPHAR | E | V | 18/07/2019 |
Spécialités Pharmaceutiques fabriquées localement :
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | Titulaire | VEIC | Type de la demande | Date BA |
1 | CIAPLUS | TADALAFIL | 10 mg | cp pell | B/16 | ADWYA | C | N | 03/07/2019 |
2 | CIPRO | CIPROFLOXACINE | 0.3% | collyre | Fl/5ml | MEDIS | E | V | 09/07/2019 |
3 | KETOTIFENE SIMED | KETOTIFENE | 1mg/5ml | sirop | Fl/150ml | SIMED | E | V | 09/07/2019 |
4 | ORECYCLINE | CHLORTETRACYCLINE | 3% | pde dermique | T/15g | SIPHAT | E | V | 09/07/2019 |